Venue | Press Room | Subscribe | Site Map
TechConnect Summit 2006
Home | About the Summit | Program | Advisory Boards | About TechConnect

Producing Sponsor

TechConnect

Platinum Sponsor

Welsh & Katz, Ltd.

Gold Sponsor

ISTC International Science & Technology Center

Ventures Enabling Sponsor

Atomic Venture Partners

Press Sponsor

Business Wire

Partnering Sponsor

NSTI

Supporting Organizations

Boston University
Midwest Research University Network

Media Sponsors

(joint with Nanotech 2006) Nature
Science
R&D Magazine

Summit News

Event Contact

Jennifer Rocha
955 Massachusetts Ave. #313
Cambridge, MA 02139
Phone: (774) 249-8514

Fullerene(C60)-vancomycin conjugates as improved antibiotics

Organization:Rice Unviersity, tx, US
I.P. Brief:This invention describes a chemical modification of vancomycin which could lead to increased antibacterial activity against resistant strains. This chemical modification involves the synthesis of new fullerene(C60)-vancomycin conjugates, containing one or more vancomycin molecules per C60 center.
Summary of I.P.:Disease-causing microbes that have become resistant to drug therapy are an increasing public health problem. About 70 percent of bacteria that cause infections in hospitals are resistant to at least one of the drugs most commonly used to treat infections. Unless antibiotic resistance problems are detected as they emerge, and actions are taken to contain them, the world could be faced with previously treatable diseases that have again become untreatable, as in the days before antibiotics were developed. This invention describes a chemical modification of vancomycin which could lead to increased antibacterial activity against resistant strains. This chemical modification involves the synthesis of new fullerene(C60)-vancomycin conjugates, containing one or more vancomycin molecules per C60 center. The antibacterial activity of other antibiotics such as penicillin, cephalosporins, fluoroquinolones etc. might also be improved as fullerene(C60)-antibiotic conjugates. In addition to vancomycin, targeting molecules can be added to the fullerene structure, generating tissue-targeting of antibiotics. One example is represented by bone targeting by further derivatization with diphosphonate groups to treat osteomyelitis.
Patent:
Keywords:antibiotic, nanotechnology, fullerene
Primary Industry:Pharma & Biotech
Specific Market:Antibiotics
Market Size:na
State of the Art:Chaneg antibiotic treatment when resistance emerges
Figures of Merit:na
Tech.  Obstacles:None
Market Obstacles:na
Publications:na
Research Team:3

 

Home | About the Summit | Program | Advisory Boards | About TechConnect
Terms of use | Privacy policy | Contact | TechConnect Home
© 2005 TechConnect. All rights reserved.